ClinicalTrials.gg
CompletedNCT02689206Updated Feb 25, 2020Results posted

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent

A Phase 2 interventional study of GSK1278863 and GSK1278863 matching Placebo in Anaemia, sponsored by GlaxoSmithKline. Completed at 38 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-25.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies testing GSK1278863 in Anemia — 1 open to participants now, 1 under way, 1 of them phase 3. GSK1278863 · Anemia.

Enrollment
12th of 30
103 · median 76
Started
2016
with 4 others
Phase 2
10 of 30
none open now
Registered
13th of 30
by date
Lead sponsor
28 of 30
GlaxoSmithKline

Among the 30 studies testing GSK1278863 in Anemia, this one is the 12th largest by enrollment, is one of 5 that started in 2016, is one of 10 in phase 2, and was the 13th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 30 studies testing GSK1278863 in Anemia is open now. Recruiting first, the newest first:

About GSK1278863

GSK1278863: first FDA approval 2023 (JESDUVROQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing GSK1278863 in Anemia, or all of them as a file.
02

Study summary

GSK1278863 is an orally available, hypoxia-inducible factor - prolyl hydroxylase inhibitor, currently being investigated as a treatment for anemia associated with chronic kidney disease. GSK1278863 has been given as a once daily regimen in clinical studies to date. However, physicians in countries that use a three-times weekly hemodialysis schedule prefer to give the anemia medicine at the same time as the dialysis session. This study will test how well GSK1278863 can maintain hemoglobin levels when given three-times weekly, for 29 days.

This study will describe the relationship between hemoglobin and GSK1278863 given three-times weekly. The data from this study will allow for conversion of once daily doses to three-times weekly doses.

03

Conditions studied

  • Anaemia

Keywords

  • Chronic kidney disease
  • Efficacy
  • Erythropoiesis-stimulating agent
  • GSK1278863
  • Safety
  • Hemodialysis-dependent anemia
  • Pharmacokinetics
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • More than or equal to 18 years of age, at the time of signing the .
  • : Stable Hemoglobin 9.0 - 11.5 gram per deciliter (g/dL).
  • Dialysis frequency: On hemodialysis (HD, hemofiltration or hemodiafiltration) three to five times weekly for at least 4 weeks prior to Day -28 Screening through Day 29.
  • Dialysis adequacy: A single pool Kt/Vurea of >=1.2 based on a historical value obtained within the prior three months in order to ensure the adequacy of dialysis. If Kt/Vurea is not available, then an average of the last 2 values of urea reduction ratio (URR) of at least 65 percent. NOTE: Only needs confirming at Day -28.
  • Erythropoiesis-stimulating agent (ESA)dose: Treated with the same ESA (epoetins or their biosimilars, or darbepoetin or methoxy polyethylene glycol [PEG]-epoetin beta) with total weekly dose varying by no more than 50 percent during the 4 weeks prior to Day -28.
  • Iron replacement therapy: Subjects may be on stable maintenance oral or intravenous (IV) (\<=100 milligram (mg)/week) iron supplementation. If subjects are on oral or IV iron, then doses must be stable for the 4 weeks prior to Day -28, during the screening phase, and through the 29 days of treatment.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and in study protocol.

Exclusion criteria

Exclusion Criteria:

  • Dialysis modality: Planned change from HD to peritoneal dialysis within the study time period.
  • Renal transplant: Planned for living-related kidney transplant.
  • High ESA dose: An epoetin dose of >=360 international unit (IU)/kilogram (kg)/week IV or >=250 IU/kg/week subcutaneous (SC) or darbepoetin dose of >=1.8 microgram (mcg)/kg/week IV or SC or methoxy PEG-epoetin beta dose of >= 2.2 mcg/kg/week within the prior 8 weeks through Day 1 (randomization).
  • Administration of methoxy PEG-epoetin beta within the prior 4 weeks through Day 1 (randomization).
  • Myocardial infarction or acute coronary syndrome: Within the 8 weeks prior to Screening through Day 1 (randomization).
  • Stroke or : Within 8 weeks prior to Screening though Day 1 (randomization).
  • Heart failure: Class IV heart failure, as defined by the (NYHA) functional classification system diagnosed prior to Screening through Day 1 (randomization).
  • Correction of Q-T Interval using Bazett's formula (): QTcB >500 millisecond (msec) or QTcB >530 msec in subjects with Bundle Branch Block. There is no correction of Q-T Interval (QTc) exclusion for subjects with a predominantly paced rhythm.
  • Inflammatory disease: Active chronic inflammatory disease that could impact erythropoiesis (e.g., scleroderma, systemic lupus erythematosis, rheumatoid arthritis, celiac disease) diagnosed prior to Screening through Day 1 (randomization).
  • Hematological disease: Any hematological disease including those affecting , white or red blood cells (e.g., sickle cell anemia, myelodysplastic syndromes, hematological , myeloma, hemolytic anemia and thalassemia), coagulation disorders (e.g., antiphospholipid syndrome, Protein C or S deficiency), or any other cause of anemia of chronic disease other than renal disease diagnosed prior to Screening though Day 1 (randomization).
  • Liver disease: Current liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones) or evidence at Screening of abnormal liver function tests [ (ALT) or aspartate transaminase (AST) >2x (ULN) or total >1.5xULN]; or other hepatic abnormalities that in the opinion of the investigator would preclude the subject from participating in the study.

NOTE: Those with or are eligible provided these exclusions are not met.

  • Major surgery: Major surgery (excluding vascular access surgery) within the 8 weeks prior to Screening, during the Screening phase, or planned during the study.
  • Transfusion: Blood transfusion within the 8 weeks prior to Screening, during the Screening phase or an anticipated need for blood transfusion during the study.
  • Gastrointestinal (GI) Bleeding: Evidence of actively bleeding peptic, duodenal, or esophageal ulcer disease OR GI bleeding within the 8 weeks prior to Screening through Day 1 (randomization).
  • Acute Infection: Clinical evidence of acute infection or history of infection requiring IV antibiotic therapy within the 4 weeks prior to Screening through Day 1 (randomization). NOTE: IV antibiotics as prophylaxis are allowed.
  • Malignancy: History of malignancy within the two years prior to randomization or currently receiving treatment for cancer, or has a known >=4 centimeter complex kidney cyst (i.e. Bosniak Category II F, III of IV). NOTE: ONLY exception is squamous cell or basal cell carcinoma of the skin that has been definitively treated >=8 weeks prior to Screening.
  • Severe allergic reactions: History of severe allergic or anaphylactic reactions or to in the product
  • Drugs and supplements: Use of any prescription or non-prescription drugs or dietary supplements that are prohibited (as per protocol) from Screening until the Follow-up Visit.
  • Prior investigational product exposure: The Subject has participated in a clinical trial and has received an experimental investigational product within the prior 30 days from Screening through Day 1 (randomization).
  • Other conditions: Any other condition, clinical or laboratory abnormality, or examination finding that the investigator considers would put the subject at unacceptable risk, which may affect study compliance or prevent understanding of the aims or investigational procedures or possible consequences of the study.
  • Females ONLY: A female subject is not eligible to participate if she is pregnant [as confirmed by a positive serum human chorionic gonadotrophin (hCG) test for females of (FRP) only], breastfeeding, and if of reproductive potential does not agree to follow one of the options listed in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in FRP.
  • Vitamin B12: At or below the lower limit of the reference range (may rescreen in a minimum of 8 weeks).
  • Folate: \<2.0 nanogram (ng) per millilitre (mL) (4.5 nanomole/liter [L]) (may rescreen in a minimum of 4 weeks).
  • Ferritin: \<100 ng/mL (\<100 mcg/L).
  • Transferrin saturation (TSAT): \<20 percent.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
103 participants (actual)

Study arms

  • Experimental
    GSK1278863 10 mg

    Subject will receive 10 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).

    Drug: GSK1278863

  • Experimental
    GSK1278863 15 mg

    Subject will receive 15 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).

    Drug: GSK1278863

  • Experimental
    GSK1278863 25 mg

    Subject will receive 25 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).

    Drug: GSK1278863

  • Experimental
    GSK1278863 30 mg

    Subject will receive 30 mg of GSK1278863 three-times weekly for 4 weeks (up to 29 days).

    Drug: GSK1278863

  • Placebo comparator
    Placebo

    Subject will receive GSK1278863 matching placebo three-times weekly for 4 weeks (up to 29 days).

    Drug: GSK1278863 matching Placebo

Interventions

  • GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.

  • DrugGSK1278863 matching Placebo

    GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hgb Levels at Day 29

    Blood samples were collected from participants for measurement of Hgb values. Baseline is the average of Hgb measured at Week -2 and Day 1 visits. Change from Baseline at Day 29 was defined as post dose value at Day 29 minus Baseline value. The analysis was performed on intent-to-treat (ITT) Population which comprised of all randomized participants who received at least one dose of study treatment, had a Baseline and at least one corresponding on treatment assessment, including Hgb.

    Time frame: Baseline and Day 29

Secondary outcomes

  1. Maximum Observed Change From Baseline in Plasma Erythropoietin (EPO)

    Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on EPO. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at each given post-Baseline time point was calculated and the maximum change from Baseline was determined.

    Time frame: Baseline and up to Day 29

  2. Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)

    Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on VEGF. Day 1 values were considered as Baseline values. The percent change from Baseline at each given post-Baseline time point was calculated (expressed as geometric mean) and the maximum percent change from Baseline was determined.

    Time frame: Baseline and up to Day 29

  3. Percent Change From Baseline in Hepcidin at Day 29

    Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on hepcidin. Day 1 values were considered as Baseline values. The Percent change from Baseline at Day 29 post-Baseline time point was calculated and expressed as geometric mean and the maximum change from Baseline was determined.

    Time frame: Baseline and Day 29

  4. Change From Baseline in Hematocrit Levels

    Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on hematocrit. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.

    Time frame: Baseline and Day 29

  5. Change From Baseline in Red Blood Cell (RBC) Count

    Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on RBC count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.

    Time frame: Baseline and Day 29

  6. Change From Baseline in Reticulocyte Count

    Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on reticulocyte count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.

    Time frame: Baseline and Day 29

  7. Change From Baseline in Reticulocyte Hemoglobin (CHr)

    Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on CHr. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.

    Time frame: Baseline and Day 29

  8. Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) and AUC From Time Zero to Infinity (AUC[0-inf]) of Dapro

    Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a "Day 1" profile for non-compartmental analysis (NCA). Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. The analysis was performed on PK Population, which comprised of all participants from whom a PK sample has been obtained and analyzed. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29

  9. Maximum Observed Concentration of Dapro in Plasma (Cmax)

    Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a "Day 1" profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated.

    Time frame: Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29

  10. Time to Reach Cmax (Tmax) and Apparent Terminal Half-life (t1/2) of Dapro

    Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a "Day 1" profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29

  11. Number of Participants Who Discontinued Study Treatment

    Reasons of study treatment discontinuation included adverse events (AEs), protocol deviation, participants reached protocol defined stopping criteria, physician decision and withdrawal by participants. Number of participants who discontinued study treatment are presented. Analysis was performed on Safety Population which comprised of all participants who received at least one dose of study treatment.

    Time frame: Up to Day 43

  12. Number of Participants With AEs and Serious Adverse Events (SAEs)

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function.

    Time frame: Up to Day 43

  13. Sodium, Potassium, Glucose, Calcium, Phosphate Levels in Blood at Indicated Time Points

    Serum sodium, potassium, glucose, corrected calcium and phosphate levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Day 43

  14. Albumin and Protein Levels in Blood at Indicated Tme Points

    Serum albumin and protein levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Day 43

  15. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase (Alk. Phosph) Levels in Blood at Indicated Time Points

    Serum ALT, AST and alk. phosph. levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Day 43

  16. Bilirubin, Direct Bilirubin and Indirect Bilirubin Levels in Blood at Indicated Time Points

    Serum bilirubin, direct bilirubin and indirect bilirubin levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Day 43

  17. Change From Baseline in Sodium, Potassium, Glucose, Calcium and Phosphate Levels

    Blood samples were collected from participants to evaluate clinical chemistry parameters including sodium, potassium, glucose, calcium and phosphate. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and up to Day 43

  18. Change From Baseline in Albumin and Protein Levels

    Blood samples were collected from participants to evaluate clinical chemistry parameters including albumin and protein. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and up to Day 43

  19. Change From Baseline in ALT, AST, Alk. Phosph. Levels

    Blood samples were collected from participants to evaluate clinical chemistry parameters including ALT, AST, Alk. phosph. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and up to Day 43

  20. Change From Baseline in Bilirubin, Direct Bilirubin, Indirect Bilirubin Levels

    Blood samples were collected from participants to evaluate clinical chemistry parameters including bilirubin, direct bilirubin and indirect bilirubin. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and up to Day 43

  21. Leukocytes, Neutrophils, Basophils, Eosinophils,Lymphocytes, Monocytes, Platelet Levels in Blood at Indicated Time Points

    Serum leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes and platelet levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Day 43

  22. Mean Corpuscular Hemoglobin (MCH) Levels in Blood at Indicated Time Points

    Serum MCH levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Day 43

  23. Mean Corpuscular Hemoglobin Concentration (MCHC) Levels in Blood at Indicated Time Points

    Serum MCHC levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Day 43

  24. Mean Corpuscular Volume (MCV) Levels in Blood at Indicated Time Points

    Serum MCV levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Day 43

  25. Erythrocyte Distribution Width Levels in Blood at Indicated Time Points

    Erythrocyte distribution width levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

    Time frame: Up to Day 43

  26. Change From Baseline in MCH Levels

    Blood samples were collected from participants to evaluate clinical hematology parameters including MCH. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and up to Day 43

  27. Change From Baseline in MCHC Levels

    Blood samples were collected from participants to evaluate clinical hematology parameters including MCHC. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and up to Day 43

  28. Change From Baseline in MCV Levels

    Blood samples were collected from participants to evaluate clinical hematology parameters including MCV. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and up to Day 43

  29. Change From Baseline in Erythrocyte Distribution Width Levels

    Blood samples were collected from participants to evaluate clinical hematology parameters including erythrocyte distribution width. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and up to Day 43

  30. Change From Baseline in Leukocytes, Neutrophils, Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets Levels

    Blood samples were collected from participants to evaluate clinical hematology parameters including leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes, platelets. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and up to Day 43

  31. Number of Participants With Abnormal Electrocardiogram (ECG) Findings at Indicated Time Points

    Single measurements of 12-lead ECG were obtained in supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT interval. Number of participants who had abnormal non clinically significant (NCS) and abnormal clinically significant (CS) ECG findings at Baseline (Week -4) and Day 29 are presented.

    Time frame: Up to Day 29

  32. Change From Baseline in ECG Mean Heart Rate

    Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure HR. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value.

    Time frame: Baseline and Day 29

  33. Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval and QTcB

    Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure PR interval, QRS duration, QT interval and QTcB. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Baseline and Day 29

  34. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Values at Pre-dialysis and Post-dialysis

    Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair at specific time points. SBP and DBP were measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Up to Day 43

  35. Pulse Rate Values at Pre-dialysis and Post-dialysis

    Vital sign measurements including pulse rate values were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Up to Day 43

  36. Weight Values at Post-dialysis

    Vital sign measurements including weight values were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Up to Day 43

  37. Change From Baseline in SBP and DBP Values at Pre-dialysis and Post-dialysis

    Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair. SBP and DBP were measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as SBP and DBP value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Up to Day 43

  38. Change From Baseline in Pulse Rate Value at Pre-dialysis and Post-dialysis

    Vital sign measurements including pulse rate were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as pulse rate value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as pulse rate value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Up to Day 43

  39. Change From Baseline in Weight at Post-dialysis

    Vital sign measurements including weight were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

    Time frame: Up to Day 43

07

Results

Posted May 21, 2018

Participant flow

Participants on Hemodialysis (HD) with anemia associated with chronic kidney disease (CKD) switching from Erythropoiesis-Stimulating Agent (ESA) treatment were recruited in this randomized, dose-ranging study. Participants with hemoglobin (Hgb) values between 9.0- 11.5 grams per deciliter (g/dL) were considered as eligible for recruitment.

Participant flow — Overall Study
MilestonePlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Started2020202122
Completed1719161714
Not completed31448
Withdrew: Adverse event00102
Withdrew: Protocol violation10012
Withdrew: Other: reached stopping criteria01234
Withdrew: Physician decision10000
Withdrew: Withdrawal by subject10100

Outcome measures

PrimaryChange From Baseline in Hgb Levels at Day 29

Blood samples were collected from participants for measurement of Hgb values. Baseline is the average of Hgb measured at Week -2 and Day 1 visits. Change from Baseline at Day 29 was defined as post dose value at Day 29 minus Baseline value. The analysis was performed on intent-to-treat (ITT) Population which comprised of all randomized participants who received at least one dose of study treatment, had a Baseline and at least one corresponding on treatment assessment, including Hgb.

Time frame:
Baseline and Day 29
Reported as:
Mean · g/dL
Change From Baseline in Hgb Levels at Day 29
g/dLPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Change From Baseline in Hgb Levels at Day 29-0.61 ± 0.646-0.19 ± 1.750-0.13 ± 1.0880.64 ± 1.4530.55 ± 1.167
Statistical analysis
  • Placebo vs Dapro 10 mg · Mean difference (final values): 0.57 · 95% CI -0.31 to 1.45Analysis using a Repeated Measures Model with terms included for baseline, treatment, time and treatment\*time. Model-adjusted treatment difference of dapro 10 mg arm from Placebo along with 95 percent CI are presented.
  • Placebo vs Dapro 15 mg · Mean difference (final values): 0.51 · 95% CI -0.40 to 1.42Analysis using a Repeated Measures Model with terms included for baseline, treatment, time and treatment\*time. Model-adjusted treatment difference of dapro 15 mg arm from Placebo along with 95 percent CI are presented.
  • Placebo vs Dapro 25 mg · Mean difference (final values): 1.47 · 95% CI 0.59 to 2.35Analysis using a Repeated Measures Model with terms included for baseline, treatment, time and treatment\*time. Model-adjusted treatment difference of dapro 25 mg arm from Placebo along with 95 percent CI are presented.
  • Placebo vs Dapro 30 mg · Mean difference (final values): 1.67 · 95% CI 0.77 to 2.57Analysis using a Repeated Measures Model with terms included for baseline, treatment, time and treatment\*time. Model-adjusted treatment difference of dapro 30 mg arm from Placebo along with 95 percent CI are presented.
SecondaryMaximum Observed Change From Baseline in Plasma Erythropoietin (EPO)

Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on EPO. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at each given post-Baseline time point was calculated and the maximum change from Baseline was determined.

Time frame:
Baseline and up to Day 29
Reported as:
Mean · International unit per liter (IU/L)
Maximum Observed Change From Baseline in Plasma Erythropoietin (EPO)
International unit per liter (IU/L)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Maximum Observed Change From Baseline in Plasma Erythropoietin (EPO)53.761 ± 132.68752.255 ± 84.892173.369 ± 95.9772302.529 ± 469.8312477.644 ± 388.9757
SecondaryMaximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)

Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on VEGF. Day 1 values were considered as Baseline values. The percent change from Baseline at each given post-Baseline time point was calculated (expressed as geometric mean) and the maximum percent change from Baseline was determined.

Time frame:
Baseline and up to Day 29
Reported as:
Geometric mean · Nanograms per liter (ng/L)
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)
Nanograms per liter (ng/L)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Maximum Observed Percent Change From Baseline in Vascular Endothelial Growth Factor (VEGF)20.35 (-0.48 to 45.55)43.75 (16.44 to 77.45)32.16 (-4.77 to 83.41)53.34 (17.17 to 100.68)76.09 (34.89 to 129.88)
SecondaryPercent Change From Baseline in Hepcidin at Day 29

Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect of dapro three times weekly dose regimens on hepcidin. Day 1 values were considered as Baseline values. The Percent change from Baseline at Day 29 post-Baseline time point was calculated and expressed as geometric mean and the maximum change from Baseline was determined.

Time frame:
Baseline and Day 29
Reported as:
Geometric mean · Micrograms per liter (µg/L)
Percent Change From Baseline in Hepcidin at Day 29
Micrograms per liter (µg/L)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Percent Change From Baseline in Hepcidin at Day 2927.81 (-12.68 to 87.08)35.37 (-1.13 to 85.34)3.83 (-17.85 to 31.24)-36.74 (-49.91 to -20.12)-36.09 (-57.24 to -4.48)
SecondaryChange From Baseline in Hematocrit Levels

Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on hematocrit. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.

Time frame:
Baseline and Day 29
Reported as:
Mean · Proportion of red blood cells in blood
Change From Baseline in Hematocrit Levels
Proportion of red blood cells in bloodPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Change From Baseline in Hematocrit Levels-0.0218 ± 0.02469-0.0127 ± 0.05396-0.0149 ± 0.053790.0150 ± 0.045110.0215 ± 0.03852
SecondaryChange From Baseline in Red Blood Cell (RBC) Count

Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on RBC count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-dose visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.

Time frame:
Baseline and Day 29
Reported as:
Mean · 10^12 cells/L
Change From Baseline in Red Blood Cell (RBC) Count
10^12 cells/LPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Change From Baseline in Red Blood Cell (RBC) Count-0.19 ± 0.263-0.12 ± 0.494-0.13 ± 0.5000.12 ± 0.4200.15 ± 0.342
SecondaryChange From Baseline in Reticulocyte Count

Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on reticulocyte count. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.

Time frame:
Baseline and Day 29
Reported as:
Mean · Percentage of reticulocyte
Change From Baseline in Reticulocyte Count
Percentage of reticulocytePlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Change From Baseline in Reticulocyte Count-0.08 ± 0.848-0.11 ± 0.803-0.04 ± 0.5810.43 ± 0.5470.09 ± 0.695
SecondaryChange From Baseline in Reticulocyte Hemoglobin (CHr)

Blood samples were collected at Day 1, Day 15 and Day 29 for pharmacodynamic analysis of effect Dapro three times weekly dose regimens on CHr. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. The change from Baseline at Day 29 post-Baseline time point was calculated.

Time frame:
Baseline and Day 29
Reported as:
Mean · Picograms (pg)
Change From Baseline in Reticulocyte Hemoglobin (CHr)
Picograms (pg)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Change From Baseline in Reticulocyte Hemoglobin (CHr)-0.15 ± 1.3750.23 ± 1.3350.26 ± 1.1030.23 ± 1.0400.59 ± 1.436
SecondaryArea Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) and AUC From Time Zero to Infinity (AUC[0-inf]) of Dapro

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a "Day 1" profile for non-compartmental analysis (NCA). Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. The analysis was performed on PK Population, which comprised of all participants from whom a PK sample has been obtained and analyzed. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29
Reported as:
Geometric mean · hour into nanograms/milliliter (h*ng/mL)
Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC[0-t]) and AUC From Time Zero to Infinity (AUC[0-inf]) of Dapro
hour into nanograms/milliliter (h*ng/mL)Dapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
AUC (0-t); n= 19, 15, 16, 14311.7 ± 91.4416.7 ± 168.6513.9 ± 396.11010 ± 92.3
AUC (0-inf); n= 12, 9, 8, 11348.2 ± 78.2383.5 ± 142.71214 ± 41.61369 ± 59.3
SecondaryMaximum Observed Concentration of Dapro in Plasma (Cmax)

Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a "Day 1" profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated.

Time frame:
Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29
Reported as:
Geometric mean · ng/mL
Maximum Observed Concentration of Dapro in Plasma (Cmax)
ng/mLDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Maximum Observed Concentration of Dapro in Plasma (Cmax)140.0 ± 104.0141.4 ± 248.8246.9 ± 311.5387.3 ± 99.4
SecondaryTime to Reach Cmax (Tmax) and Apparent Terminal Half-life (t1/2) of Dapro

Blood samples were collected at indicated time points for PK analysis of dapro. The data from each PK sampling day was combined to generate a single profile, and normalized to a 24-hour period to create a "Day 1" profile for NCA. Metabolite plasma concentrations were analyzed but PK parameters could not be calculated as the metabolites were partially eliminated through dialysis and the dialysis start and end times were not consistent on both PK days. Therefore, a representative metabolite PK profile could not be generated. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Pre-dose on Day 1; 6-10 hours, 7-11 hours, 8-12 hours, 9-13 hours post dose on Day 15; pre-dose and 1, 2, 3 hours post-dose on Day 29
Reported as:
Geometric mean · Hour
Time to Reach Cmax (Tmax) and Apparent Terminal Half-life (t1/2) of Dapro
HourDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Tmax; n= 19, 15, 16, 142.456 ± 78.92.106 ± 82.12.297 ± 96.51.718 ± 58.0
T1/2; n= 12, 9, 8, 112.086 ± 50.01.886 ± 62.31.418 ± 58.42.897 ± 38.7
SecondaryNumber of Participants Who Discontinued Study Treatment

Reasons of study treatment discontinuation included adverse events (AEs), protocol deviation, participants reached protocol defined stopping criteria, physician decision and withdrawal by participants. Number of participants who discontinued study treatment are presented. Analysis was performed on Safety Population which comprised of all participants who received at least one dose of study treatment.

Time frame:
Up to Day 43
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Treatment
ParticipantsPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
AEs00101
Protocol deviation10012
Participant reached stopping criteria01234
Physician decision10000
Withdrawal by subject10100
SecondaryNumber of Participants With AEs and Serious Adverse Events (SAEs)

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function.

Time frame:
Up to Day 43
Reported as:
Number · Participants
Number of Participants With AEs and Serious Adverse Events (SAEs)
ParticipantsPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Any AE1010677
Any SAE43213
SecondarySodium, Potassium, Glucose, Calcium, Phosphate Levels in Blood at Indicated Time Points

Serum sodium, potassium, glucose, corrected calcium and phosphate levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · Millimoles per liter (mmol/L)
Sodium, Potassium, Glucose, Calcium, Phosphate Levels in Blood at Indicated Time Points
Millimoles per liter (mmol/L)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Sodium; Day 1; n= 18, 20, 20, 22, 22138.8 ± 2.85138.1 ± 2.31138.7 ± 2.83139.4 ± 2.38138.4 ± 1.76
Sodium; Day 15; n= 17, 20, 18, 22, 20137.7 ± 3.16137.5 ± 2.72138.1 ± 1.60138.0 ± 2.36137.2 ± 1.74
Sodium; Day 29; n= 17, 19, 18, 19, 17137.8 ± 3.96136.8 ± 2.70137.9 ± 2.85138.8 ± 2.74137.1 ± 2.46
Sodium; Day 43; n= 15, 20, 18, 21, 21139.2 ± 2.88138.1 ± 1.77137.9 ± 2.37138.8 ± 2.02137.6 ± 1.88
Potassium; Day 1; n= 18, 20, 20, 22, 224.68 ± 0.8404.73 ± 0.7684.64 ± 0.8264.79 ± 0.5144.83 ± 0.685
Potassium; Day 15; n= 17, 20, 18, 22, 204.72 ± 0.7634.77 ± 0.5424.57 ± 0.6354.82 ± 0.7654.80 ± 0.791
Potassium; Day 29; n= 17, 19, 18, 19, 174.78 ± 0.9194.87 ± 0.7514.57 ± 0.4724.86 ± 0.6194.96 ± 0.941
Potassium; Day 43; n= 15, 20, 18, 21, 214.69 ± 0.9514.68 ± 0.5624.59 ± 0.6574.76 ± 0.7524.80 ± 0.946
Glucose; Day 1; n= 18, 20, 20, 22, 226.66 ± 3.0886.66 ± 2.7166.41 ± 3.5077.05 ± 2.4918.95 ± 5.012
Glucose; Day 15; n= 17, 20, 18, 22, 207.89 ± 3.4257.16 ± 2.8447.03 ± 3.2367.26 ± 2.8528.67 ± 4.198
Glucose; Day 29; n= 17, 19, 18, 19, 178.21 ± 4.9517.49 ± 3.9497.21 ± 3.9537.77 ± 4.6218.75 ± 5.708
Glucose; Day 43; n= 15, 20, 18, 21, 216.93 ± 3.1266.72 ± 2.9657.09 ± 3.5336.27 ± 1.9588.93 ± 4.280
Calcium corrected; Day 1; n= 18, 20, 20, 22, 222.286 ± 0.21162.270 ± 0.12442.241 ± 0.16752.219 ± 0.15892.215 ± 0.1163
Calcium corrected; Day 15; n= 17, 20, 18, 22, 202.261 ± 0.16982.219 ± 0.12522.213 ± 0.17232.188 ± 0.13602.203 ± 0.1111
Calcium corrected; Day 29; n= 17, 19, 18, 19, 172.205 ± 0.14312.248 ± 0.13522.244 ± 0.15772.198 ± 0.13432.225 ± 0.1810
Calcium corrected; Day 43; n= 15, 20, 18, 21, 212.251 ± 0.15822.235 ± 0.15932.271 ± 0.18232.201 ± 0.12062.256 ± 0.1473
Phosphate; Day 1; n= 18, 20, 20, 22, 221.608 ± 0.51431.528 ± 0.55571.498 ± 0.52651.318 ± 0.36471.566 ± 0.4269
Phosphate; Day 15; n= 17, 20, 18, 22, 201.621 ± 0.42211.710 ± 0.39121.642 ± 0.50211.348 ± 0.31381.645 ± 0.4785
Phosphate; Day 29; n= 17, 19, 18, 19, 171.709 ± 0.58721.592 ± 0.41211.644 ± 0.53221.453 ± 0.44891.550 ± 0.3575
Phosphate; Day 43; n= 15, 20, 18, 21, 211.550 ± 0.58281.460 ± 0.45501.472 ± 0.42401.412 ± 0.44411.398 ± 0.4718
SecondaryAlbumin and Protein Levels in Blood at Indicated Tme Points

Serum albumin and protein levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · grams per liter (g/L)
Albumin and Protein Levels in Blood at Indicated Tme Points
grams per liter (g/L)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Albumin; Day 1; n= 18, 20, 20, 22, 2237.6 ± 2.8938.6 ± 2.4638.7 ± 3.8438.8 ± 2.2238.1 ± 3.52
Albumin; Day 15; n= 17, 20, 18, 22, 2038.1 ± 2.6838.1 ± 2.6538.4 ± 3.4238.4 ± 2.5237.2 ± 3.01
Albumin; Day 29; n= 17, 19, 18, 19, 1736.5 ± 3.2237.2 ± 3.2637.6 ± 3.6237.4 ± 2.1736.9 ± 4.15
Albumin; Day 43; n= 15, 20, 18, 21, 2137.1 ± 2.8538.1 ± 3.0237.9 ± 3.9539.0 ± 3.1137.5 ± 2.86
Protein; Day 1; n= 18, 20 ,20, 22, 2267.3 ± 4.9066.9 ± 5.4267.4 ± 4.8966.4 ± 5.1665.7 ± 4.65
Protein; Day 15; n= 17, 20, 18, 22, 2068.1 ± 4.8766.5 ± 4.8867.3 ± 4.2865.6 ± 5.1364.3 ± 4.70
Protein; Day 29; n= 17, 19, 18, 19, 1766.1 ± 4.5265.7 ± 4.7566.0 ± 4.5165.5 ± 6.5065.3 ± 5.30
Protein; Day 43; n= 15, 20, 18, 21, 2167.2 ± 4.2567.4 ± 5.1466.8 ± 4.0266.7 ± 7.7066.6 ± 6.34
SecondaryAlanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase (Alk. Phosph) Levels in Blood at Indicated Time Points

Serum ALT, AST and alk. phosph. levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · IU/L
Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Alkaline Phosphatase (Alk. Phosph) Levels in Blood at Indicated Time Points
IU/LPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
ALT; Day 1; n= 18, 20, 20, 22, 2212.6 ± 9.3613.4 ± 7.5114.6 ± 11.3910.7 ± 5.7511.5 ± 5.94
ALT; Day 15; n= 17, 20, 18, 22, 2016.5 ± 13.8013.9 ± 10.5812.4 ± 7.8711.9 ± 6.588.4 ± 2.11
ALT; Day 29; n= 17, 19, 18, 19, 1724.4 ± 32.3412.8 ± 6.4312.2 ± 6.4010.9 ± 5.678.6 ± 3.12
ALT; Day 43; n= 15, 20, 18, 21, 2114.3 ± 8.5513.8 ± 8.0312.8 ± 6.8913.1 ± 5.1911.2 ± 5.57
AST; Day 1; n= 18, 20, 20, 22, 2214.9 ± 5.5814.2 ± 5.1917.2 ± 12.3114.4 ± 5.8513.6 ± 3.63
AST; Day 15; n= 17, 20, 18, 22, 2017.1 ± 7.3014.3 ± 5.6715.0 ± 7.7215.4 ± 6.3312.4 ± 2.89
AST; Day 29; n= 17, 19, 18, 19, 1726.8 ± 30.0413.8 ± 5.0116.0 ± 8.4415.0 ± 6.3513.5 ± 3.12
AST; Day 43; n= 15, 20, 18, 21, 2115.9 ± 6.6514.9 ± 6.0717.2 ± 11.4015.7 ± 6.3114.3 ± 4.76
Alk. phosph; Day 1; n= 18, 20, 20, 22, 2297.0 ± 33.07112.3 ± 74.61106.8 ± 84.8599.4 ± 47.26115.4 ± 72.35
Alk. phosph; Day 15; n= 17, 20, 18, 22,20102.4 ± 34.70115.4 ± 73.37114.5 ± 82.29101.5 ± 56.44110.0 ± 62.65
Alk. phosph.; Day 29; n= 17, 19, 18, 19,1794.1 ± 35.07120.2 ± 81.15109.2 ± 83.1493.5 ± 42.92120.4 ± 67.51
Alk. phosph.; Day 43; n= 15, 20, 18, 21,2196.5 ± 34.12117.6 ± 76.61113.8 ± 78.69116.2 ± 96.02108.6 ± 50.49
SecondaryBilirubin, Direct Bilirubin and Indirect Bilirubin Levels in Blood at Indicated Time Points

Serum bilirubin, direct bilirubin and indirect bilirubin levels were assessed as a clinical chemistry laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · Micromoles per liter (µmol/L)
Bilirubin, Direct Bilirubin and Indirect Bilirubin Levels in Blood at Indicated Time Points
Micromoles per liter (µmol/L)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Bilirubin; Day 1; n= 18, 20, 20, 22, 226.6 ± 1.657.8 ± 3.116.6 ± 1.316.5 ± 1.107.2 ± 2.44
Bilirubin; Day 15; n= 17, 20, 18, 22, 206.7 ± 3.087.1 ± 2.297.2 ± 2.676.5 ± 1.107.8 ± 2.24
Bilirubin; Day 29; n= 17, 19, 18, 19, 176.8 ± 2.246.9 ± 1.937.6 ± 2.126.5 ± 1.477.8 ± 2.44
Bilirubin; Day 43; n= 15, 20 ,18, 21, 216.0 ± 1.077.0 ± 2.387.2 ± 2.076.5 ± 1.257.5 ± 2.44
Direct bilirubin; Day 1; n= 18, 20, 20, 22, 221.8 ± 1.171.9 ± 0.792.0 ± 1.121.9 ± 0.752.4 ± 1.33
Direct bilirubin; Day 15; n= 17, 20, 18, 22, 201.5 ± 1.662.2 ± 0.622.4 ± 1.291.8 ± 0.852.6 ± 1.14
Direct bilirubin; Day 29; n= 17, 19, 18, 19,172.5 ± 2.291.6 ± 1.072.7 ± 0.971.8 ± 0.632.4 ± 1.46
Direct bilirubin; Day 43; n= 15, 20, 18, 21,211.3 ± 1.231.9 ± 0.452.3 ± 0.771.7 ± 0.722.3 ± 1.31
Indirect bilirubin; Day 1; n= 18, 20, 20, 22, 224.8 ± 1.225.9 ± 2.944.6 ± 0.944.6 ± 1.144.8 ± 1.92
Indirect bilirubin; Day 15; n= 17, 20, 18, 22, 205.2 ± 2.014.9 ± 2.104.8 ± 1.834.7 ± 0.985.2 ± 1.77
Indirect bilirubin; Day 29; n= 17, 19, 18, 19, 174.4 ± 2.035.4 ± 1.644.9 ± 1.574.7 ± 1.525.4 ± 1.70
Indirect bilirubin; Day 43; n= 15, 20, 18, 21, 214.7 ± 0.985.1 ± 2.384.9 ± 1.414.8 ± 1.485.2 ± 1.73
SecondaryChange From Baseline in Sodium, Potassium, Glucose, Calcium and Phosphate Levels

Blood samples were collected from participants to evaluate clinical chemistry parameters including sodium, potassium, glucose, calcium and phosphate. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and up to Day 43
Reported as:
Mean · Mmol/L
Change From Baseline in Sodium, Potassium, Glucose, Calcium and Phosphate Levels
Mmol/LPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Sodium; Day 15; n= 17, 20, 18, 22, 20-0.9 ± 2.73-0.6 ± 2.62-0.5 ± 2.64-1.4 ± 2.06-1.0 ± 2.13
Sodium; Day 29; n= 17, 19, 18, 19, 17-1.1 ± 2.26-1.2 ± 3.08-0.9 ± 2.26-0.5 ± 2.82-1.2 ± 2.70
Sodium; Day 43; n= 15, 20, 18, 21, 210.7 ± 2.060.1 ± 2.35-0.6 ± 2.28-0.5 ± 2.60-0.6 ± 2.23
Potassium; Day 15; n= 17, 20, 18, 22, 200.04 ± 0.4620.05 ± 0.526-0.09 ± 1.0990.03 ± 0.944-0.08 ± 0.635
Potassium; Day 29; n= 17, 19, 18, 19, 170.20 ± 0.7440.05 ± 0.660-0.14 ± 0.6510.02 ± 0.6400.11 ± 0.673
Potassium; Day 43; n= 15, 20, 18, 21, 210.04 ± 0.565-0.05 ± 0.674-0.06 ± 1.004-0.06 ± 0.579-0.02 ± 0.932
Glucose; Day 15; n= 17, 20, 18, 22, 201.14 ± 3.3390.51 ± 2.9590.45 ± 1.7400.21 ± 1.620-0.03 ± 2.364
Glucose; Day 29; n= 17, 19, 18, 19, 171.48 ± 3.7710.70 ± 3.7560.73 ± 1.1350.61 ± 4.188-0.36 ± 3.786
Glucose; Day 43; n= 15, 20, 18, 21, 210.23 ± 1.3350.06 ± 3.0720.52 ± 1.383-0.81 ± 2.516-0.12 ± 3.619
Calcium; Day 15; n= 17, 20, 18, 22, 20-0.011 ± 0.1227-0.051 ± 0.1354-0.026 ± 0.1439-0.031 ± 0.0956-0.010 ± 0.0912
Calcium; Day 29; n= 17, 19, 18, 19, 17-0.054 ± 0.1486-0.025 ± 0.1129-0.009 ± 0.1556-0.012 ± 0.09390.001 ± 0.1019
Calcium; Day 43; n= 15, 20, 18, 21, 21-0.015 ± 0.1576-0.035 ± 0.12610.018 ± 0.18520.001 ± 0.07420.033 ± 0.1489
Phosphate; Day 15; n= 17, 20, 18, 22, 20-0.091 ± 0.40510.183 ± 0.51840.111 ± 0.57150.030 ± 0.32680.095 ± 0.3367
Phosphate; Day 29; n= 17, 19, 18, 19, 170.091 ± 0.38820.011 ± 0.49320.069 ± 0.49500.129 ± 0.2740-0.026 ± 0.3653
Phosphate; Day 43; n= 15, 20, 18, 21, 21-0.067 ± 0.4337-0.068 ± 0.5324-0.053 ± 0.54000.102 ± 0.3433-0.117 ± 0.5117
SecondaryChange From Baseline in Albumin and Protein Levels

Blood samples were collected from participants to evaluate clinical chemistry parameters including albumin and protein. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and up to Day 43
Reported as:
Mean · g/L
Change From Baseline in Albumin and Protein Levels
g/LPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Albumin; Day 15; n= 17, 20, 18, 22, 200.8 ± 1.60-0.5 ± 1.640.2 ± 2.24-0.5 ± 1.44-1.0 ± 2.34
Albumin; Day 29; n= 17, 19, 18, 19, 17-0.5 ± 2.24-1.3 ± 2.03-0.7 ± 2.00-1.3 ± 1.85-0.9 ± 1.76
Albumin; Day 43; n= 15, 20, 18, 21, 210.1 ± 2.00-0.6 ± 2.14-0.7 ± 2.220.1 ± 3.85-0.3 ± 1.74
Protein; Day 15; n= 17, 20, 18, 22, 200.8 ± 2.97-0.4 ± 3.250.3 ± 3.65-0.7 ± 2.35-1.5 ± 3.03
Protein; Day 29; n= 17, 19, 18, 19, 17-1.1 ± 4.26-0.8 ± 3.82-1.2 ± 2.90-1.0 ± 3.280.1 ± 2.56
Protein; Day 43; n= 15, 20, 18, 21, 21-0.1 ± 4.190.6 ± 4.38-0.9 ± 3.170.3 ± 4.841.2 ± 3.95
SecondaryChange From Baseline in ALT, AST, Alk. Phosph. Levels

Blood samples were collected from participants to evaluate clinical chemistry parameters including ALT, AST, Alk. phosph. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and up to Day 43
Reported as:
Mean · IU/L
Change From Baseline in ALT, AST, Alk. Phosph. Levels
IU/LPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
ALT; Day 15; n= 17, 20, 18, 22, 203.6 ± 9.590.5 ± 5.65-3.1 ± 5.531.1 ± 4.79-3.4 ± 5.52
ALT; Day 29; n= 17, 19, 18, 19, 1711.8 ± 32.39-0.9 ± 4.65-3.4 ± 9.83-0.2 ± 3.87-3.6 ± 4.72
ALT; Day 43; n= 15, 20, 18, 21, 210.9 ± 4.320.4 ± 5.29-2.5 ± 8.972.2 ± 4.08-0.4 ± 3.69
AST; Day 15; n= 17, 20, 18, 22, 202.3 ± 5.700.1 ± 2.45-2.7 ± 6.291.0 ± 5.26-1.6 ± 3.32
AST; Day 29; n= 17, 19, 18, 19, 1711.5 ± 30.64-0.3 ± 3.30-1.8 ± 5.600.9 ± 3.60-0.3 ± 3.67
AST; Day 43; n= 15, 20, 18, 21, 210.6 ± 3.940.7 ± 2.49-0.6 ± 7.991.5 ± 3.710.7 ± 3.41
Alk.phosph.; Day 15; n= 17, 20, 18, 22, 203.2 ± 10.283.2 ± 16.132.7 ± 29.732.1 ± 17.23-4.7 ± 18.90
Alk.phosph.; Day 29; n= 17, 19, 18, 19, 17-0.4 ± 19.315.1 ± 19.09-0.9 ± 30.130.9 ± 13.47-1.2 ± 28.60
Alk.phosph.; Day 43; n= 15, 20, 18, 21, 21-1.5 ± 17.015.4 ± 21.342.7 ± 31.9618.0 ± 66.44-8.4 ± 56.06
SecondaryChange From Baseline in Bilirubin, Direct Bilirubin, Indirect Bilirubin Levels

Blood samples were collected from participants to evaluate clinical chemistry parameters including bilirubin, direct bilirubin and indirect bilirubin. Change from Baseline in clinical chemistry parameters at Day 15, Day 29 and Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and up to Day 43
Reported as:
Mean · µmol/L
Change From Baseline in Bilirubin, Direct Bilirubin, Indirect Bilirubin Levels
µmol/LPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Bilirubin; Day 15; n= 17, 20, 18, 22, 200.2 ± 1.56-0.7 ± 1.490.8 ± 2.070.0 ± 1.380.5 ± 1.93
Bilirubin; Day 29; n= 17, 19, 18, 19, 170.2 ± 0.97-0.3 ± 1.201.0 ± 1.410.1 ± 1.560.2 ± 0.97
Bilirubin; Day 43; n= 15, 20, 18, 21, 21-0.1 ± 0.52-0.8 ± 1.510.6 ± 2.040.1 ± 1.340.4 ± 1.36
Direct bilirubin; Day 15; n= 17, 20, 18, 22, 20-0.1 ± 1.110.3 ± 0.730.6 ± 0.92-0.1 ± 0.970.2 ± 1.11
Direct bilirubin; Day 29; n= 17, 19, 18, 19, 170.7 ± 1.86-0.3 ± 1.000.7 ± 0.97-0.1 ± 1.05-0.1 ± 1.50
Direct bilirubin; Day 43; n= 15, 20, 18, 21, 21-0.1 ± 1.190.0 ± 0.920.3 ± 1.03-0.2 ± 1.08-0.1 ± 1.34
Indirect bilirubin; Day 15; n= 17, 20, 18, 22, 200.4 ± 1.46-1.0 ± 1.380.2 ± 1.800.1 ± 1.440.3 ± 1.75
Indirect bilirubin; Day 29; n= 17, 19, 18, 19, 17-0.5 ± 1.660.0 ± 1.150.3 ± 1.710.2 ± 1.620.4 ± 1.46
Indirect bilirubin; Day 43; n= 15, 20, 18, 21, 210.0 ± 1.07-0.8 ± 1.640.2 ± 1.660.3 ± 1.820.5 ± 1.40
SecondaryLeukocytes, Neutrophils, Basophils, Eosinophils,Lymphocytes, Monocytes, Platelet Levels in Blood at Indicated Time Points

Serum leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes and platelet levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · 10^12 cells/L
Leukocytes, Neutrophils, Basophils, Eosinophils,Lymphocytes, Monocytes, Platelet Levels in Blood at Indicated Time Points
10^12 cells/LPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Leukocytes; Day 1; n= 18, 19, 19, 20, 216.28 ± 1.7506.07 ± 1.6015.88 ± 1.5106.44 ± 1.5955.90 ± 1.825
Leukocytes; Day 15; n= 17, 19, 17, 21, 217.01 ± 2.1405.85 ± 1.7206.21 ± 1.9186.52 ± 1.4275.87 ± 1.961
Leukocytes; Day 29; n= 16, 19, 17, 18, 176.66 ± 1.7076.59 ± 1.8905.88 ± 1.6856.33 ± 1.8206.11 ± 2.574
Leukocytes; Day 43; n= 16, 20, 19, 20, 197.05 ± 2.0067.25 ± 2.5206.00 ± 1.6946.77 ± 2.5476.42 ± 2.010
Neutrophils; Day 1; n= 18, 19, 19, 20, 214.030 ± 1.61284.097 ± 1.57633.522 ± 1.34923.954 ± 1.40973.785 ± 1.5024
Neutrophils; Day 15; n= 17, 19, 17, 21, 214.666 ± 1.81133.887 ± 1.56593.707 ± 1.65924.346 ± 1.22404.129 ± 1.6604
Neutrophils; Day 29; n= 16, 18, 17, 17, 154.123 ± 1.22294.591 ± 1.95863.522 ± 1.45463.978 ± 1.70264.224 ± 2.2017
Neutrophils; Day 43; n= 16, 20, 19, 19, 194.687 ± 1.89195.049 ± 2.38483.545 ± 1.40274.477 ± 2.24804.343 ± 1.6235
Basophils; Day 1; n= 18, 19, 19, 20, 210.018 ± 0.01310.016 ± 0.01340.025 ± 0.01740.028 ± 0.02040.017 ± 0.0142
Basophils; Day 15; n= 17, 19, 17, 21, 210.027 ± 0.02140.026 ± 0.01610.022 ± 0.01390.025 ± 0.03250.024 ± 0.0140
Basophils; Day 29; n= 16, 18, 17, 17, 150.035 ± 0.04620.021 ± 0.01280.021 ± 0.01500.024 ± 0.01110.027 ± 0.0315
Basophils; Day 43; n= 16, 20, 19, 19, 190.028 ± 0.02170.018 ± 0.01360.020 ± 0.01830.025 ± 0.02040.024 ± 0.0130
Eosinophils; Day 1; n= 18, 19, 19, 20, 210.189 ± 0.19460.174 ± 0.15930.184 ± 0.16960.196 ± 0.23100.240 ± 0.2115
Eosinophils; Day 15; n= 17, 19, 17, 21, 210.161 ± 0.12450.166 ± 0.18040.192 ± 0.23550.187 ± 0.21860.186 ± 0.1914
Eosinophils; Day 29; n= 16, 18, 17, 17, 150.176 ± 0.19170.149 ± 0.09500.145 ± 0.11360.237 ± 0.27850.185 ± 0.0798
Eosinophils; Day 43; n= 16, 20, 19, 19, 190.216 ± 0.24580.210 ± 0.19690.232 ± 0.27270.243 ± 0.26700.217 ± 0.1899
Lymphocytes; Day 1; n= 18, 19, 19, 20, 211.631 ± 0.42641.393 ± 0.45871.739 ± 0.69641.747 ± 0.73251.442 ± 0.4998
Lymphocytes; Day 15; n= 17, 19, 17, 21, 211.735 ± 0.66991.416 ± 0.56701.842 ± 0.73811.526 ± 0.66971.206 ± 0.4609
Lymphocytes; Day 29; n= 16, 18, 17, 17, 151.870 ± 0.74271.427 ± 0.41871.775 ± 0.67671.612 ± 0.57751.181 ± 0.3418
Lymphocytes; Day 43; n= 16, 20, 19, 19, 191.648 ± 0.52941.509 ± 0.43861.736 ± 0.39161.721 ± 0.66441.399 ± 0.5562
Monocytes; Day 1; n= 18, 19, 20, 20, 210.401 ± 0.15110.396 ± 0.15910.435 ± 0.27030.518 ± 0.20770.421 ± 0.1722
Monocytes; Day 15; n= 17, 19, 17, 21, 210.420 ± 0.22430.352 ± 0.14570.436 ± 0.24020.446 ± 0.20850.384 ± 0.2160
Monocytes; Day 29; n= 16, 18, 17, 17, 150.444 ± 0.20760.457 ± 0.15030.403 ± 0.13850.600 ± 0.34650.426 ± 0.2628
Monocytes; Day 43; n= 16, 20, 19, 19, 190.461 ± 0.18780.459 ± 0.19160.461 ± 0.26140.513 ± 0.27390.429 ± 0.2047
Platelet; Day 1; n= 16, 19, 20, 19, 21219.0 ± 65.04189.9 ± 36.70198.0 ± 71.03196.0 ± 61.12192.3 ± 70.85
Platelet; Day 15; n= 17, 18, 17, 20, 21205.4 ± 63.00175.4 ± 44.08198.5 ± 73.65194.8 ± 49.08181.5 ± 66.59
Platelet; Day 29; n= 16, 19, 17, 17, 17198.1 ± 76.39174.7 ± 52.50187.5 ± 62.66198.9 ± 55.07194.8 ± 81.57
Platelet; Day 43; n= 15, 20, 19, 21, 20220.8 ± 61.57195.8 ± 68.33188.6 ± 69.28194.1 ± 50.35170.0 ± 44.61
SecondaryMean Corpuscular Hemoglobin (MCH) Levels in Blood at Indicated Time Points

Serum MCH levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · Pg
Mean Corpuscular Hemoglobin (MCH) Levels in Blood at Indicated Time Points
PgPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Day 1; n= 18, 19, 20, 20, 2131.19 ± 2.53830.95 ± 1.88930.19 ± 2.14530.70 ± 1.78131.46 ± 1.942
Day 15; n= 17, 19, 17, 21, 2130.83 ± 2.1002.100 ± 1.86630.74 ± 1.47630.85 ± 1.61931.70 ± 2.315
Day 29; n= 16, 19, 17, 18, 1730.97 ± 2.29031.60 ± 2.19430.56 ± 2.23631.16 ± 1.72931.68 ± 2.224
Day 43; n= 16, 20, 19, 21, 2030.86 ± 1.99231.04 ± 1.87030.49 ± 2.15530.67 ± 1.84631.84 ± 2.143
SecondaryMean Corpuscular Hemoglobin Concentration (MCHC) Levels in Blood at Indicated Time Points

Serum MCHC levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · g/L
Mean Corpuscular Hemoglobin Concentration (MCHC) Levels in Blood at Indicated Time Points
g/LPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Day 1; n= 18, 19, 20, 20, 21322.9 ± 13.39321.7 ± 12.61319.5 ± 15.36321.5 ± 12.91327.6 ± 12.65
Day 15; n= 17, 19, 17, 21, 21321.5 ± 11.22324.0 ± 7.79324.8 ± 8.35318.3 ± 12.06322.7 ± 14.75
Day 29; n= 16, 19, 17, 18, 17323.3 ± 14.90329.6 ± 12.61325.4 ± 10.25323.6 ± 8.61323.9 ± 11.73
Day 43; n= 16, 20, 19, 21, 20321.9 ± 13.22325.2 ± 11.98325.5 ± 11.23321.0 ± 11.00327.0 ± 10.66
SecondaryMean Corpuscular Volume (MCV) Levels in Blood at Indicated Time Points

Serum MCV levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · Femtoliter (fL)
Mean Corpuscular Volume (MCV) Levels in Blood at Indicated Time Points
Femtoliter (fL)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Day 1; n= 18, 19, 20, 20, 2196.7 ± 5.9496.4 ± 5.6894.7 ± 5.2895.7 ± 4.9196.1 ± 5.61
Day 15; n= 17, 19, 17, 21, 2195.9 ± 6.0295.8 ± 6.2794.8 ± 4.5397.0 ± 6.4198.3 ± 5.57
Day 29; n= 16, 19, 17, 18, 1795.8 ± 5.8395.9 ± 6.0594.1 ± 5.9496.3 ± 4.7697.8 ± 4.96
Day 43; n= 16, 20, 19, 21, 2096.1 ± 5.9195.4 ± 5.0893.7 ± 6.0995.6 ± 5.2797.5 ± 5.98
SecondaryErythrocyte Distribution Width Levels in Blood at Indicated Time Points

Erythrocyte distribution width levels were assessed as a clinical hematology laboratory parameter from Baseline up to follow up visit at Day 43. Day 1 values were considered as Baseline values. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · Percentage of width
Erythrocyte Distribution Width Levels in Blood at Indicated Time Points
Percentage of widthPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Day 1; n= 18, 19, 20, 20, 2115.13 ± 2.60716.40 ± 2.08215.41 ± 1.62715.81 ± 2.50415.68 ± 1.725
Day 15; n= 17, 19, 17, 21, 2115.05 ± 2.08815.77 ± 1.56915.26 ± 1.19716.30 ± 2.33116.74 ± 1.912
Day 29; n= 16, 19, 17, 18, 1715.15 ± 2.53015.69 ± 1.75015.36 ± 1.28715.76 ± 1.25316.23 ± 1.668
Day 43; n= 16, 20, 19, 21, 2015.53 ± 2.86615.53 ± 2.01814.95 ± 1.26915.61 ± 1.29715.48 ± 1.389
SecondaryChange From Baseline in MCH Levels

Blood samples were collected from participants to evaluate clinical hematology parameters including MCH. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and up to Day 43
Reported as:
Mean · Pg
Change From Baseline in MCH Levels
PgPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Day 15; n= 17, 19, 17, 21, 210.16 ± 0.6020.19 ± 0.8170.27 ± 0.6850.16 ± 0.5200.25 ± 0.870
Day 29; n= 16, 19, 17, 18, 170.16 ± 0.9820.58 ± 1.1850.42 ± 0.8240.41 ± 0.7440.15 ± 0.987
Day 43; n= 16, 20, 19, 21, 200.11 ± 0.9810.13 ± 0.9480.34 ± 0.9930.11 ± 0.8420.29 ± 0.809
SecondaryChange From Baseline in MCHC Levels

Blood samples were collected from participants to evaluate clinical hematology parameters including MCHC. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and up to Day 43
Reported as:
Mean · g/L
Change From Baseline in MCHC Levels
g/LPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Day 15; n= 17, 19, 17, 21, 212.6 ± 11.093.0 ± 14.213.5 ± 10.87-3.2 ± 11.48-5.0 ± 12.92
Day 29; n= 16, 19, 17, 18, 175.6 ± 12.817.3 ± 16.927.6 ± 8.270.8 ± 10.04-4.4 ± 12.30
Day 43; n= 16, 20, 19, 21, 203.9 ± 15.923.0 ± 16.536.0 ± 11.44-1.0 ± 12.12-0.3 ± 9.14
SecondaryChange From Baseline in MCV Levels

Blood samples were collected from participants to evaluate clinical hematology parameters including MCV. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and up to Day 43
Reported as:
Mean · fL
Change From Baseline in MCV Levels
fLPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Day 15; n= 17, 19, 17, 21, 21-0.4 ± 2.98-0.2 ± 3.39-0.3 ± 2.571.3 ± 3.152.2 ± 3.21
Day 29; n= 16, 19, 17, 18, 17-1.4 ± 3.24-0.5 ± 2.86-0.9 ± 2.360.9 ± 2.541.6 ± 2.40
Day 43; n= 16, 20, 19, 21, 20-0.8 ± 3.15-0.7 ± 3.37-0.8 ± 3.280.6 ± 3.060.9 ± 2.10
SecondaryChange From Baseline in Erythrocyte Distribution Width Levels

Blood samples were collected from participants to evaluate clinical hematology parameters including erythrocyte distribution width. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and up to Day 43
Reported as:
Mean · Percentage of width
Change From Baseline in Erythrocyte Distribution Width Levels
Percentage of widthPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Day 15; n= 17, 19, 17, 21, 21-0.18 ± 1.025-0.48 ± 1.276-0.09 ± 1.0470.54 ± 1.1621.06 ± 1.337
Day 29; n= 16, 19, 17, 18, 17-0.31 ± 1.019-0.64 ± 1.332-0.23 ± 1.0210.58 ± 1.2020.40 ± 1.342
Day 43; n= 16, 20, 19, 21, 200.18 ± 1.329-0.74 ± 1.728-0.50 ± 1.0940.23 ± 1.410-0.22 ± 1.165
SecondaryChange From Baseline in Leukocytes, Neutrophils, Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets Levels

Blood samples were collected from participants to evaluate clinical hematology parameters including leukocytes, neutrophils, basophils, eosinophils, lymphocytes, monocytes, platelets. Change from Baseline in clinical hematology parameters at Day 15, Day 29, Day 43 are presented. Day 1 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and up to Day 43
Reported as:
Mean · 10^12 cells/L
Change From Baseline in Leukocytes, Neutrophils, Basophils, Eosinophils, Lymphocytes, Monocytes, Platelets Levels
10^12 cells/LPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Leukocytes; Day 15; n= 17, 19, 17, 21, 210.47 ± 1.271-0.21 ± 1.0510.40 ± 1.116-0.03 ± 1.476-0.03 ± 1.463
Leukocytes; Day 29; n= 16, 19, 17, 18, 170.49 ± 1.8490.40 ± 1.7840.00 ± 1.084-0.14 ± 1.7010.20 ± 1.526
Leukocytes; Day 43; n= 16, 20, 19, 20, 190.54 ± 1.0411.08 ± 1.6620.23 ± 1.1010.21 ± 2.6150.67 ± 1.580
Neutrophils; Day 15; n= 17, 19, 17, 21, 210.391 ± 1.2323-0.146 ± 0.91630.280 ± 1.06810.259 ± 1.38740.344 ± 1.2469
Neutrophils; Day 29; n= 16, 18, 17, 17, 150.237 ± 1.62830.469 ± 1.5717-0.021 ± 1.0157-0.009 ± 1.87180.273 ± 1.5729
Neutrophils; Day 43; n= 16, 20, 19, 19, 190.423 ± 1.05350.904 ± 1.37370.112 ± 1.04490.504 ± 2.31100.691 ± 1.5221
Basophils; Day 15; n= 17, 19, 17, 21, 210.005 ± 0.03020.009 ± 0.0200-0.002 ± 0.0210-0.002 ± 0.03830.007 ± 0.0102
Basophils; Day 29; n= 16, 18, 17, 17, 150.013 ± 0.05100.006 ± 0.0195-0.004 ± 0.01870.000 ± 0.02420.012 ± 0.0328
Basophils; Day 43; n= 16, 20, 19, 19, 190.006 ± 0.02680.001 ± 0.0148-0.004 ± 0.0203-0.001 ± 0.02280.007 ± 0.0192
Eosinophils; Day 15; n= 17, 19, 17, 21, 210.009 ± 0.0698-0.017 ± 0.1313-0.006 ± 0.1345-0.006 ± 0.1183-0.053 ± 0.1478
Eosinophils; Day 29; n= 16, 18, 17, 17, 150.020 ± 0.0859-0.002 ± 0.1226-0.006 ± 0.11290.025 ± 0.09900.007 ± 0.0880
Eosinophils; Day 43; n= 16, 20, 19, 19, 190.061 ± 0.11930.030 ± 0.14390.051 ± 0.16470.021 ± 0.0984-0.024 ± 0.1876
Lymphocytes; Day 15; n= 17, 19, 17, 21, 210.082 ± 0.4256-0.019 ± 0.31630.106 ± 0.4617-0.208 ± 0.5095-0.236 ± 0.4298
Lymphocytes; Day 29; n= 16, 18, 17, 17, 150.194 ± 0.66050.026 ± 0.41300.019 ± 0.4421-0.074 ± 0.7018-0.154 ± 0.3058
Lymphocytes; Day 43; n= 16, 20, 19, 19, 190.018 ± 0.34270.061 ± 0.33320.007 ± 0.4824-0.064 ± 0.4759-0.041 ± 0.2801
Monocytes; Day 15; n= 17, 19, 17, 21, 21-0.005 ± 0.1518-0.042 ± 0.1504-0.016 ± 0.2285-0.068 ± 0.1895-0.037 ± 0.1460
Monocytes; Day 29; n= 16, 18, 17, 17, 150.027 ± 0.15530.053 ± 0.1483-0.031 ± 0.21940.077 ± 0.25320.015 ± 0.1878
Monocytes; Day 43; n= 16, 20, 19, 19, 190.033 ± 0.16310.065 ± 0.16290.026 ± 0.2652-0.021 ± 0.18550.023 ± 0.1249
Platelet; Day 15; n= 17, 18, 17, 20, 21-14.2 ± 26.24-16.2 ± 27.46-3.2 ± 38.13-3.3 ± 27.78-10.8 ± 31.95
Platelet; Day 29; n= 16, 18, 17, 17, 17-17.1 ± 40.58-12.8 ± 36.55-18.1 ± 29.631.3 ± 35.58-2.4 ± 33.65
Platelet; Day 43; n= 15, 19, 19, 21, 20-4.9 ± 37.304.4 ± 50.34-10.4 ± 35.12-1.6 ± 30.95-7.1 ± 31.95
SecondaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings at Indicated Time Points

Single measurements of 12-lead ECG were obtained in supine position using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT interval. Number of participants who had abnormal non clinically significant (NCS) and abnormal clinically significant (CS) ECG findings at Baseline (Week -4) and Day 29 are presented.

Time frame:
Up to Day 29
Reported as:
Number · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings at Indicated Time Points
ParticipantsPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Baseline(Week -4);Abnormal; NCS;n=19,20,20,22,221015181216
Baseline(Week-4);Abnormal;CS;n=19,20,20,22,2200010
Day 29; Abnormal; NCS; n=17,19,18,19,17121416812
Day 29; Abnormal; CS; n=17,19,18,19,1700010
SecondaryChange From Baseline in ECG Mean Heart Rate

Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure HR. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value.

Time frame:
Baseline and Day 29
Reported as:
Mean · Beats per minute
Change From Baseline in ECG Mean Heart Rate
Beats per minutePlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Change From Baseline in ECG Mean Heart Rate-2.0 ± 8.660.5 ± 10.531.1 ± 7.402.2 ± 7.510.9 ± 7.09
SecondaryChange From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval and QTcB

Single measurements of 12-lead ECG were obtained in supine position using an ECG machine to measure PR interval, QRS duration, QT interval and QTcB. Week -4 values were considered as Baseline values. Change from Baseline was calculated by subtracting post-Baseline visit values at Day 29 minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Baseline and Day 29
Reported as:
Mean · Milliseconds (msec)
Change From Baseline in ECG Parameters Including PR Interval, QRS Duration, QT Interval and QTcB
Milliseconds (msec)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
PR interval; n= 17, 18, 18, 17, 167.8 ± 16.867.3 ± 12.37-3.3 ± 23.042.1 ± 27.13-11.5 ± 24.77
QRS duration; n= 17, 19, 18, 19, 17-1.4 ± 14.05-5.7 ± 13.36-4.7 ± 47.011.7 ± 14.332.5 ± 8.97
QT interval; n= 17, 19, 18, 19, 1710.5 ± 27.160.7 ± 31.11-19.2 ± 62.37-1.4 ± 17.72-8.2 ± 33.24
QTcB; n= 17, 19, 18, 19, 170.0 ± 30.845.6 ± 17.40-3.7 ± 44.861.1 ± 20.84-5.7 ± 31.65
SecondarySystolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Values at Pre-dialysis and Post-dialysis

Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair at specific time points. SBP and DBP were measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · Millimeter of mercury (mmHg)
Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Values at Pre-dialysis and Post-dialysis
Millimeter of mercury (mmHg)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
SBP; pre-dialysis; Day 1; n= 19, 20, 20, 22, 22142.5 ± 22.15136.6 ± 15.39149.2 ± 26.36144.1 ± 24.27144.1 ± 17.01
SBP; pre-dialysis; Day 15; n= 17, 20, 18, 22, 21138.8 ± 24.12138.3 ± 16.14139.0 ± 22.77146.6 ± 20.75142.3 ± 14.90
SBP; pre-dialysis; Day 29; n= 17, 19, 18, 19, 17143.0 ± 22.08133.1 ± 18.65143.1 ± 23.21144.2 ± 23.27148.7 ± 19.17
SBP; pre-dialysis; Day 43; n= 16, 20, 19, 21, 21140.0 ± 22.01137.9 ± 13.21142.0 ± 24.23149.0 ± 23.32147.1 ± 19.18
DBP; pre-dialysis; Day 1; n= 19, 20, 20, 22, 2271.9 ± 14.8468.8 ± 11.0273.3 ± 12.9671.8 ± 14.3872.2 ± 13.64
DBP; pre-dialysis; Day 15; n= 17, 20, 18, 22, 2172.5 ± 17.7670.0 ± 11.9270.1 ± 10.5073.5 ± 13.6969.7 ± 12.43
DBP; pre-dialysis; Day 29; n= 17, 19, 18, 19, 1770.4 ± 15.4363.5 ± 13.5570.9 ± 12.8673.3 ± 13.1772.7 ± 9.96
DBP; pre-dialysis; Day 43; n= 16, 20, 19, 21, 2172.5 ± 14.7366.8 ± 11.9469.9 ± 13.5477.9 ± 16.0372.8 ± 10.52
SBP; post-dialysis; Day 1; n= 19, 20, 20, 22, 22138.6 ± 18.57137.0 ± 22.10139.9 ± 22.24136.7 ± 21.15140.1 ± 20.10
SBP; post-dialysis; Day 15; n= 17, 20, 18, 22, 21138.6 ± 21.83135.5 ± 21.63137.7 ± 23.02137.4 ± 17.58140.9 ± 15.34
SBP; post-dialysis; Day 29; n= 17, 19, 18, 19, 17135.7 ± 26.04130.1 ± 18.50133.7 ± 23.88142.8 ± 23.96147.8 ± 19.09
SBP; post-dialysis; Day 43; n= 16, 20, 19, 21, 21137.5 ± 22.74135.8 ± 21.05130.4 ± 15.47145.2 ± 20.66137.5 ± 22.74
DBP; post-dialysis; Day 1; n= 19, 20, 20, 22, 2272.1 ± 15.1167.9 ± 11.4968.7 ± 11.6471.1 ± 12.9271.5 ± 11.17
DBP; post-dialysis; Day 15; n= 17, 20, 18, 22, 2172.4 ± 16.4170.1 ± 12.8467.8 ± 11.1071.3 ± 11.0771.1 ± 9.51
DBP; post-dialysis; Day 29; n= 17, 19, 18, 19, 1773.9 ± 15.1164.4 ± 9.8367.9 ± 12.0072.4 ± 12.4372.9 ± 11.18
DBP; post-dialysis; Day 43; n= 16, 20, 19, 21, 2169.5 ± 15.2467.4 ± 10.9067.4 ± 11.2472.9 ± 12.6075.3 ± 7.89
SecondaryPulse Rate Values at Pre-dialysis and Post-dialysis

Vital sign measurements including pulse rate values were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · Beats per minute
Pulse Rate Values at Pre-dialysis and Post-dialysis
Beats per minutePlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Pre-dialysis; Day 1; n= 19, 20, 20, 22, 2268.5 ± 7.9569.9 ± 9.1866.7 ± 7.0171.4 ± 11.2576.5 ± 9.35
Pre-dialysis; Day 15; n= 17, 20, 18, 22, 2176.1 ± 10.3167.3 ± 9.2068.3 ± 7.5172.1 ± 11.8975.1 ± 12.68
Pre-dialysis; Day 29; n= 17, 19, 18, 19, 1770.4 ± 8.3170.3 ± 11.5469.6 ± 9.5370.8 ± 9.9173.4 ± 11.45
Pre-dialysis; Day 43; n= 16, 20, 19, 21, 2171.5 ± 9.1769.9 ± 9.3466.9 ± 6.7471.3 ± 10.0875.8 ± 8.29
Post-dialysis; Day 1; n= 19, 20, 20, 22, 2271.0 ± 11.5468.7 ± 11.1966.3 ± 8.3773.2 ± 12.7778.8 ± 11.61
Post-dialysis; Day 15; n= 17, 20, 18, 22, 2172.5 ± 12.6967.7 ± 12.2470.1 ± 12.4973.0 ± 12.0778.1 ± 15.72
Post-dialysis; Day 29; n= 17, 19, 18, 19, 1773.6 ± 7.1069.9 ± 9.6068.8 ± 11.2972.2 ± 9.5277.4 ± 10.04
Post-dialysis; Day 43; n= 16, 20, 19, 21, 2172.0 ± 12.0469.1 ± 10.2168.0 ± 10.2871.9 ± 11.0277.3 ± 10.26
SecondaryWeight Values at Post-dialysis

Vital sign measurements including weight values were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · Kilograms (kg)
Weight Values at Post-dialysis
Kilograms (kg)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Day 1; n= 19, 20, 20, 22, 2282.38 ± 25.94180.04 ± 25.99678.83 ± 21.33179.38 ± 23.34576.03 ± 16.877
Day 15; n= 17, 20, 18, 22, 2184.24 ± 26.65280.00 ± 25.88779.82 ± 22.20079.44 ± 23.50075.55 ± 17.595
Day 29; n= 17, 19, 18, 19, 1783.22 ± 27.19881.04 ± 25.92580.02 ± 22.28682.66 ± 23.03676.07 ± 18.135
Day 43; n= 16, 20, 19, 21, 2183.93 ± 27.58980.21 ± 26.68379.25 ± 21.75780.64 ± 23.34773.66 ± 11.614
SecondaryChange From Baseline in SBP and DBP Values at Pre-dialysis and Post-dialysis

Vital sign measurements including SBP and DBP were taken in a seated or semi-supine position in the dialysis chair. SBP and DBP were measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as SBP and DBP value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · mmHg
Change From Baseline in SBP and DBP Values at Pre-dialysis and Post-dialysis
mmHgPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
SBP; pre-dialysis; Day 15; n= 17, 20, 18, 22, 21-2.9 ± 22.031.7 ± 14.14-5.6 ± 14.772.5 ± 20.68-1.4 ± 16.35
SBP; pre-dialysis; Day 29; n= 17, 19, 18, 19, 17-0.6 ± 20.32-3.9 ± 19.72-4.7 ± 18.171.3 ± 17.514.5 ± 20.03
SBP; pre-dialysis; Day 43; n= 16, 20, 19, 21, 21-2.1 ± 21.341.2 ± 17.14-6.2 ± 13.833.3 ± 19.474.3 ± 10.03
SBP; post-dialysis; Day 15; n= 17, 20, 18, 22, 215.4 ± 21.39-3.6 ± 20.136.1 ± 20.815.7 ± 21.07-0.7 ± 22.33
SBP; post-dialysis; Day 29; n= 17, 19, 18, 19, 172.3 ± 19.72-9.4 ± 18.500.8 ± 24.799.3 ± 19.034.0 ± 19.76
SBP; post-dialysis; Day 43; n= 16, 20, 19, 21, 213.1 ± 22.22-3.2 ± 21.71-3.6 ± 17.8812.0 ± 20.194.7 ± 20.11
DBP; pre-dialysis; Day 15; n= 17, 20, 18, 22, 211.1 ± 10.571.2 ± 8.85-1.7 ± 9.781.8 ± 12.68-2.1 ± 11.04
DBP; pre-dialysis; Day 29; n= 17, 19, 18, 19, 17-0.3 ± 11.09-4.7 ± 10.04-3.0 ± 8.991.4 ± 10.50-0.1 ± 13.80
DBP; pre-dialysis; Day 43; n= 16, 20, 19, 21, 212.2 ± 8.80-2.0 ± 9.47-3.1 ± 11.065.2 ± 15.082.1 ± 11.00
DBP; post-dialysis; Day 15; n= 17, 20, 18, 22, 212.4 ± 11.412.4 ± 7.71-2.9 ± 11.113.6 ± 9.84-0.8 ± 14.13
DBP; post-dialysis; Day 29; n= 17, 19, 18, 19, 173.7 ± 12.93-2.5 ± 8.52-3.2 ± 11.614.1 ± 9.330.2 ± 10.59
DBP; post-dialysis; Day 43; n= 16, 20, 19, 21, 21-0.6 ± 10.07-0.3 ± 9.53-3.8 ± 12.134.5 ± 9.994.8 ± 10.28
SecondaryChange From Baseline in Pulse Rate Value at Pre-dialysis and Post-dialysis

Vital sign measurements including pulse rate were taken in a seated or semi-supine position in the dialysis chair. Pulse rate was measured pre-dialysis and post-dialysis. Pre-dialysis Baseline value was defined as pulse rate value obtained pre-dialysis on Day 1. Post-dialysis Baseline value was defined as pulse rate value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · Beats per minute
Change From Baseline in Pulse Rate Value at Pre-dialysis and Post-dialysis
Beats per minutePlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Pre-dialysis; Day 15; n= 17, 20, 18, 22, 217.0 ± 9.50-2.6 ± 8.462.3 ± 5.760.7 ± 11.46-1.4 ± 11.15
Pre-dialysis; Day 29; n= 17, 19, 18, 19, 172.4 ± 6.920.9 ± 12.863.4 ± 7.580.5 ± 10.01-3.0 ± 9.14
Pre-dialysis; Day 43; n= 16, 20, 19, 21, 213.1 ± 9.590.1 ± 6.570.8 ± 6.11-0.6 ± 10.030.2 ± 6.79
Post-dialysis; Day 15; n= 17, 20, 18, 22, 212.2 ± 11.61-1.2 ± 12.861.1 ± 10.150.5 ± 8.004.4 ± 13.28
Post-dialysis; Day 29; n= 17, 19, 18, 19, 174.2 ± 9.131.5 ± 13.13-0.8 ± 9.792.6 ± 9.046.0 ± 7.50
Post-dialysis; Day 43; n= 16, 20, 19, 21, 212.3 ± 8.670.3 ± 12.96-0.8 ± 9.32-0.1 ± 9.083.9 ± 9.32
SecondaryChange From Baseline in Weight at Post-dialysis

Vital sign measurements including weight were taken in a seated or semi-supine position in the dialysis chair. Weight was measured post-dialysis. Post-dialysis Baseline value was defined as SBP and DBP value obtained post-dialysis at Week -2. Change from Baseline was calculated by subtracting post-Baseline visit values minus Baseline value. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles).

Time frame:
Up to Day 43
Reported as:
Mean · kg
Change From Baseline in Weight at Post-dialysis
kgPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Day 15; n= 17, 20, 18, 22, 21-0.16 ± 0.6340.16 ± 0.971-0.01 ± 0.6170.06 ± 0.799-0.31 ± 1.215
Day 29; n= 17, 19, 18, 19, 17-0.11 ± 1.053-0.05 ± 1.583-1.23 ± 5.913-0.16 ± 1.046-0.19 ± 1.244
Day 43; n= 16, 20, 19, 21, 21-0.21 ± 0.6650.37 ± 2.760-1.39 ± 5.7590.15 ± 1.4720.33 ± 2.169

Adverse events

Collected over On-therapy serious adverse events (SAEs) and non-serious adverse events (AEs) are presented from the start of study treatment to the end of the 29-day study treatment period plus 1 day, inclusive; an average of 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/19 (0%)2/19 (10.5%)5/19 (26.3%)
Dapro 10 mg0/20 (0%)3/20 (15%)8/20 (40%)
Dapro 15 mg0/20 (0%)2/20 (10%)4/20 (20%)
Dapro 25 mg0/22 (0%)1/22 (4.5%)2/22 (9.1%)
Dapro 30 mg0/22 (0%)2/22 (9.1%)0/22 (0%)
Most frequent serious events
Most frequent serious events
EventPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
Cardiac failure congestiveCardiac disorders0/192/200/200/220/22
Arteriovenous fistula thrombosisInjury, poisoning and procedural complications1/190/200/200/220/22
Orthostatic hypotensionVascular disorders1/190/200/200/220/22
Angina unstableCardiac disorders0/191/200/200/221/22
Mesenteric artery stenosisGastrointestinal disorders0/190/201/200/220/22
Post procedural myocardial infarctionInjury, poisoning and procedural complications0/191/200/200/220/22
Hypertensive crisisVascular disorders0/190/201/200/220/22
Fluid overloadMetabolism and nutrition disorders0/190/200/201/221/22
Most frequent other events
Showing 10 of 23
Most frequent other events
EventPlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mg
DiarrhoeaGastrointestinal disorders0/192/200/200/220/22
AstheniaGeneral disorders1/190/201/200/220/22
Helicobacter gastritisInfections and infestations1/190/200/200/220/22
DehydrationMetabolism and nutrition disorders1/190/200/200/220/22
Musculoskeletal painMusculoskeletal and connective tissue disorders1/190/200/200/220/22
DizzinessNervous system disorders1/191/200/200/220/22
HeadacheNervous system disorders1/190/200/200/220/22
Bundle branch block leftCardiac disorders0/190/201/200/220/22
HyperparathyroidismEndocrine disorders0/191/200/200/220/22
DyspepsiaGastrointestinal disorders0/190/201/200/220/22

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mgTotal
Mean61.0 ± 13.0663.6 ± 16.9859.5 ± 12.2667.2 ± 15.2265.4 ± 13.9763.4 ± 14.39
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mgTotal
Female11869842
Male91214121461
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboDapro 10 mgDapro 15 mgDapro 25 mgDapro 30 mgTotal
Race customized — African American/African Heritage6675630
Race customized — American Indian Or Alaskan Native010012
Race customized — Asian - Central/South Asian Heritage011002
Race customized — Native Hawaiian Or Other Pacific Islander000101
Race customized — White- Arabic/North African Heritage000101
Race customized — White-White/Caucasian/European Heritage141212141567
08

Study locations

38 sites
  • GSK Investigational Site
    Northridge, California 91324, United States
  • GSK Investigational Site
    San Dimas, California 91773, United States
  • GSK Investigational Site
    Pembroke Pines, Florida 33028, United States
  • GSK Investigational Site
    Greenbelt, Maryland 20770, United States
  • GSK Investigational Site
    Roseville, Michigan 48066, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    Bronx, New York 10461, United States
  • GSK Investigational Site
    Calgary, Alberta T2R 0X7, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 7W9, Canada
  • GSK Investigational Site
    Toronto, Ontario M3M 0B2, Canada
  • GSK Investigational Site
    Greenfield Park, Quebec J4V 2H1, Canada
  • GSK Investigational Site
    Stuttgart, Baden-Wuerttemberg 70376, Germany
  • GSK Investigational Site
    Villingen-Schwenningen, Baden-Wuerttemberg 78054, Germany
  • GSK Investigational Site
    Kiel, Schleswig-Holstein 24105, Germany
  • GSK Investigational Site
    Darmstadt, 64295, Germany
  • GSK Investigational Site
    Krasnodar, 350029, Russian Federation
  • GSK Investigational Site
    Moscow, 129327, Russian Federation
  • GSK Investigational Site
    Mytischi, 141009, Russian Federation
  • GSK Investigational Site
    Omsk, 644112, Russian Federation
  • GSK Investigational Site
    Penza, 440034, Russian Federation
  • GSK Investigational Site
    St-Petersburg, 197110, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 194354, Russian Federation
  • GSK Investigational Site
    Yaroslavl, 150062, Russian Federation
  • GSK Investigational Site
    Almería, 04009, Spain
  • GSK Investigational Site
    Badalona, 08916, Spain
  • GSK Investigational Site
    Barcelona, 08003, Spain
  • GSK Investigational Site
    Granollers, Barcelona, 08041, Spain
  • GSK Investigational Site
    L'Hospitalet de Llobregat, 08907, Spain
  • GSK Investigational Site
    Lleida, 25198, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28100, Spain
  • GSK Investigational Site
    Malaga, 29010, Spain
  • GSK Investigational Site
    Manises (Valencia), 46940, Spain
  • GSK Investigational Site
    San Sebastian de los Reyes, 28702, Spain
  • GSK Investigational Site
    Santander, 39008, Spain
  • GSK Investigational Site
    Santiago de Compostela, 15706, Spain
  • GSK Investigational Site
    Valladolid, 47005, Spain
09

References and documents

Publications

  • Bailey CK, Caltabiano S, Cobitz AR, Huang C, Mahar KM, Patel VV. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis. BMC Nephrol. 2019 Oct 16;20(1):372. doi: 10.1186/s12882-019-1547-z. PubMed 31619187 ↗
  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Jan 2017, 11 months.

Results were first posted in May 2018, 1 year 3 months after primary completion.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 11 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2016
First posted
Feb 23, 2016
StartActual
Feb 17, 2016
Primary completionActual
Jan 25, 2017
CompletionActual
Jan 25, 2017
Results first posted
May 21, 2018
Last update
Feb 25, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02689206
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Feb 23, 2016
Start date
Feb 17, 2016
Primary completion
Jan 25, 2017
Completion
Jan 25, 2017
Results posted
May 21, 2018
Last update
Feb 25, 2020

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GSK1278863

Start the discussion